Montag, 6. Mai 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

Supramarginal Resection in Glioblastoma

Rekrutierend

NCT-Nummer:
NCT04243005

Studienbeginn:
Juli 2020

Letztes Update:
15.12.2023

Wirkstoff:
-

Indikation (Clinical Trials):
Glioblastoma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
St. Olavs Hospital

Collaborator:
Odense University Hospital, Sahlgrenska University Hospital, Sweden, Turku University Hospital, Karolinska University Hospital, Norwegian University of Science and Technology, University Hospital, Linkoeping, Uppsala University Hospital, University Hospital, Ume

Studienleiter

Asgeir S Jakola, MD, PhD
Principal Investigator
St.Olavs University Hospital and Sahlgrenska University Hospital
Geir Bråthen, MD, PhD
Study Director
St. Olavs Hospital

Kontakt

Studienlocations
(3 von 18)

Alle anzeigen

Studien-Informationen

Brief Summary:

Gliomas are the most common malignant brain tumor. Glioblastoma, WHO grade IV astrocytoma, is

the most common subtype and unfortunately also the most aggressive subtype with median

survival in population based cohorts being only 10 months. Extensive surgical resections

followed by postoperative fractioned radiotherapy and concomitant and adjuvant temozolomide

prolong survival and is the standard treatment.

The investigators think there is significant potential in individualized surgical

decision-making in glioblastoma management. The idea that some patients are amendable to

radical surgery, while others should be treated more conservatively, is not controversial in

other fields of oncology. The current concept in all patients with glioblastoma is "maximum

safe resection of the contrast enhancing tumor", but this may in selected cases be extended

to simply "maximum safe resection" tailored to the patient and extent of disease at hand.

Densely proliferating tumor cells have been found from at an average of 10 mm beyond the

margins of contrast enhancement in high-grade gliomas. There are now several case series,

using various definitions of supramarginal resection, but they have in common that they

report a benefit of resection with a margin. This potential benefit also comes together with

an associated neurological risk, making this approach unethical and simply not feasible in

the patients with glioblastoma as a whole.

Objective of this study is: To investigate if resection with a margin, that is significantly

beyond the radiological contrast enhancement, improves survival in selected patients with

glioblastoma.

Ein-/Ausschlusskriterien

Inclusion Criteria:

1. A suspected diagnosis of supratentorial glioblastoma by MRI.(A)

2. Indication for surgical treatment and where supramarginal resection is considered

possible according to the preoperative imaging. This consideration needs to be

verified by two specialists in neurosurgery.

3. Negative work-up for other primary tumor(B)

4. Karnofsky performance status of 70 - 100.

A) If randomized to supramarginal surgery, intraoperative frozen section must conclude with

"high-grade glioma" to be able to proceed. Surgery in two sessions is also possible in

supramarginal group if there is no intraoperative frozen section available or frozen

section indicate another diagnosis, but final histopathology reveals a glioblastoma. In

case of surgery in two session, there must be no more than 30 days between procedures. See

flow-chart in attachment 1.

B) No suspected primary tumor seen on CT chest, abdomen and pelvis. If relevant

symptoms/clinical suspicion also supplement with mammography, dermatologist exam, relevant

endoscopies etc.

Exclusion Criteria:

1. Not willing to be randomized.

2. Informed consent not possible (e.g. language barriers, aphasia, cognitive severely

impaired).

3. Contrast enhancement volume bilateral OR involving corpus callosum.

4. Contrast enhancement along the ependymal lining of ventricles (contact is however not

an exclusion criteria).

5. Contrast enhancement involving several lobes.

6. History of major psychiatric disorder such as psychosis, schizophrenia and/or mood

disorder (e.g. depression and bipolar disorder) in need of hospitalization

7. Unfit for participation for any other reason judged by the including physician

Studien-Rationale

Primary outcome:

1. Overall survival (Time Frame - 36 months after the last included patient.):
Overall survival according to intention-to-treat



Secondary outcome:

1. Proportion alive (Time Frame - 24 months after randomization.):
Proportion alive

2. Proportion alive (Time Frame - 36 months after randomization.):
Proportion alive

3. Neurological function (Time Frame - Early postoperative (i.e. prior to radiotherapy) to 36 months):
Neurological assessment in Neuro-Oncology (NANO) Scale is a tool used by healthcare providers to objectively quantify the impairment caused by a tumor within the central nervous system. The NANO is composed of 9 items. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NANO scale score. The maximum possible score is 23, with the minimum score being a 0.

4. Health-related quality of life assessed by EQ-5D 3L (Time Frame - Early postoperative (i.e. prior to radiotherapy) to 36 months):
The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

5. Health-related quality of life assessed by EORTC QLQ C30 (Time Frame - Early postoperative (i.e. prior to radiotherapy) to 36 months):
The QLQ-C30 is a cancer health-related quality-of-life questionnaire that has been widely used in clinical trials and investigations using PROs for individual patient management. It includes five function domains (physical, emotional, social, role, cognitive), eight symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss), as well as global health/quality-of-life and financial impact. Subjects respond on a four-point scale from "not at all" to "very much" for most items. Most items use a "past week" recall period. Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function and higher levels of symptom burden.

6. Health-related quality of life assessed by BN20 (Time Frame - Early postoperative (i.e. prior to radiotherapy) to 36 months):
The European Organization for Research and Treatment of Cancer (EORTC) QLQ-BN20 is a quality of life assessment specific to brain neoplasms. Consists of 20 items that assess future uncertainty, visual disorder, motor dysfunction, and communication deficit. Items are presented as questions on a scale ranging from 1 = "not at all" to 4 = "very much." Higher score means worse outcome.

7. Neurocognition (Time Frame - Early postoperative (i.e. prior to radiotherapy) to 36 months):
The Mini-Mental State Examination (MMSE) or Folstein test is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment. It examines functions including registration (repeating named prompts), attention and calculation, recall, language, ability to follow simple commands and orientation. Any score of 24 or more (out of 30) indicates a normal cognition. Below this, scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment.

8. Surgical complication (Time Frame - 30 days):
surgical complication grade 3, 4 and 5, assessed using the Dindo-Clavien classification

9. Proportion with contrast remnant (Time Frame - Within 72 hours postoperative):
Resection proportion with contrast remnant

10. Extent of resection, T2/FLAIR remnant (Time Frame - Within 72 hours postoperative):
Proportion with remnant in terms of hyper intensity changes in T2/FLAIR

11. Margin of resection (Time Frame - Within 72 hours postoperative):
Cavity volume/contrast enhancement volume

Studien-Arme

  • Active Comparator: Conventional surgery
    Aim of gross total resection (i.e. removal of contrast enhancing tumor) according to institutional practice. No limit in use of technical adjuncts in this arm.
  • Experimental: Supramarginal surgery
    Aim of supramarginal resection, where a margin of at least 10 mm is considered feasible prior to surgery. The resection is guided by the T2 volume (i.e. zone of edema) where removal of as much as possible of this zone (or beyond) is attempted as long as considered safe

Geprüfte Regime

  • Supramarginal resection:
    Aim of supramarginal resection, where a margin of at least 10 mm is considered feasible prior to surgery. The resection is guided by the T2 volume (i.e. zone of edema) where removal of as much as possible of this zone (or beyond) is attempted as long as considered safe
  • Conventional surgery:
    Aim of gross total resection (i.e. removal of contrast enhancing tumor) according to institutional practice. No limit in use of technical adjuncts in this arm.

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Supramarginal Resection in Glioblastoma"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.